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Common Respiratory
DiseasesDavid Kilgore, MD, Wadie Najm, MD, MSEd*KEYWORDS
 Complementary and alternative medicine
 Herbals  Upper respiratory infections
 Chronic obstructive pulmonary disease
 Asthma  RhinosinusitisThe incidence of acute respiratory conditions in the United States and around the
world (eg, West Nile virus, influenza A virus subtype H1N1, severe acute respiratory
syndrome) and the burden of chronic respiratory conditions (eg, asthma, chronic
obstructive pulmonary disease [COPD]) continue to increase and cause concern.
Human parainfluenza viruses (HPIVs) and respiratory syncytial virus (RSV) are
a common cause of upper respiratory tract disease in young children. They spread
from contact with respiratory secretions on contaminated surfaces or close contact
with infected persons. No curative treatment or vaccines are currently available to
protect against infection caused by any of these viruses.
RSV can cause substantial morbidity in older adults. Although RSV and influenza
cause considerable individual morbidity, the burden of disease from rhinovirus infec-
tions and infections of unknown etiology seems greater. The interval between onset of
illness and consultation together with diagnostic difficulties raises concern regarding
the role of antiviral drugs in treating influenza.
Asthma is also common. Recent data from the Centers for Disease Control and
Prevention (CDC) (www.cdc.gov) indicate that 16.2 million adults and 6.7 million chil-
dren currently have asthma, resulting in 10.6 million visits to office-based physicians
and a minimum of 444,000 hospital stays.
COPD (a group of diseases characterized by airflow obstruction associated with
breathing-related symptoms) was the underlying cause of death for 718,077 persons
aged 25 years and older in the United States between 2000 and 2005. From 2000 to
2005, the annual number of deaths from COPD increased 5% among men and 11%
among women.
Studies about the use of complementary and alternative medicine (CAM) have
documented a high use of CAM therapies for conditions that are chronic and lackDepartment of Family Medicine, Irvine School of Medicine, University of California, 101 The
City Drive South, Building 200, Suite 512, Irvine, Orange, CA 92868, USA
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Kilgore & Najm298a cure such as asthma,1 rhinosinusitis,2 and COPD.3 In this article, the authors review
the most common natural therapies used for the treatment of the common cold, rhi-
nosinusitis, asthma, and COPD.COMMON COLD
Viral upper respiratory infection (URI) accounts for a high number of people missing
work or school, and represents the leading acute diagnosis in the office setting
each year in the United States alone.4 The common cold is caused by several viral
organisms such as adenoviruses, myxoviruses, coronaviruses, picornaviruses. The
most common viral cause is the Rhinovirus (10%–25%). Usually, patients recover in
7 to 10 days. Complications are usually related to extension of infection to the lower
respiratory tract (eg, bronchitis, pneumonia) or nasal ostia and eustachian tubes
(eg, sinusitis, otitis media). Usual care is mainly symptomatic and supportive. The
most commonly known or marketed natural supplements are described in this article.
However, health professionals should know that herbalists and natural health care
providers most often use a combination of herbs, supplement, aromatherapy, and
so forth. to treat symptoms or for their antimicrobial properties. Discussion of such
formulas is beyond the scope of this article. A summary is presented in Table 1.
Andrographis (Andrographis paniculata)
Andrographis paniculata is an annual herb. The leaves are used traditionally in Asian
traditional medicine and particularly Ayurveda to treat fever associated with infections.
Approximately 28 species of Andrographis are known and indigenous to Asia. A pan-
iculata is the most commonly used. Andrographis is also used for other medical condi-
tions; for example, digestive problems, blood cleanser, fever, sore throat, and URIs.
In a systematic review by Coon and Ernst5 in 2004, 7 double-blind controlled trials
(N5 896) met the criteria for evaluation of efficacy. All trials scored at least 3 out of 5 in
methodological qualities. The dose of Andrographis used ranged from 48 to 360 mg. A
paniculata alone or in combination with E senticosus seem promising in the treatment
of uncomplicated URI symptoms. In the highest quality study6 a fixed combination of
standardized extract of the leaves of A paniculata 60 mg/d and the roots of E sentico-
sus 120 mg/d given to patients with uncomplicated URIs within 36 hours of the onset
of symptoms. Outcome measures were patient and physician evaluation of severity of
symptoms based on predefined criteria. Significant improvement was noted in
patient-measured symptoms (P 5 .0006) and physician-measured assessments
(P 5 .003). Improvement was noted in symptoms such as muscle ache, cough
frequency, presence of productive cough, fever, and sore throat.
Another meta-analysis published in the same year identified 4 qualifying studies
(N 5 433) and reported similar improvements in symptom severity in favor of the
combination A paniculata and E senticosus.7 A large (N 5 200) nonrandomized study,
using the same fixed combination of standardized extract (leaves of A paniculata 60
mg/d and the roots of E senticosus 120 mg/d) given for 5 days, found a significant
difference between the mean symptom scores between groups at the end of the treat-
ment (P<.001).8 Headaches, nasal and throat symptoms, and general malaise showed
the most improvement. In another 2 randomized controlled trials, subjects received 60
mg/d of A paniculata with 48 to 72 hours of the onset of URI symptoms; statistically
significant improvement in symptoms was reported within 4 to 5 days.9,10 In a study
comparing 180 or 360 mg/d of A paniculata with paracetamol (3.9 g/d), subjects
randomized to paracetamol and high-dose A paniculata reported statistically signifi-
cant improvement in symptoms by day 3.
Table 1
Summary of natural supplements used for the treatment of the common cold
Name
Suggested
Dose Drug Interactions Side Effects
Scientific Evidence
of Efficacy
Andrographis
paniculata
48–360 mg/d No specific
interactions
noted. In vivo
and in vitro can
inhibit the
activity of
CYP2C9 and
CYP3A4
Allergic reaction; 3
reports of
anaphylactic
shock (1) or
reaction (2)
Avoid if
attempting to
conceive
Good evidence of
effectiveness
Vitamin C
(ascorbic
acid)
2–8 g/d Diarrhea, renal
lithiasis in high
doses
Equivocal
Goldenseal
(Hydrastis
canadensis)
250–500
mg/d of
extract or
dried root
Interacts with
CYP450–3A4 in
vivo, but no
known evidence
in vitro
Well tolerated.
Low evidence of
gastrointestinal
problems,
ulceration,
nephritis. Avoid
during
breastfeeding
No well-designed
studies
Echinacea sp 1–5 g/d in 3
divided
doses of
crude herb
No documented
drug interaction,
but is known to
inhibit activity of
CYP450–3A4
Well tolerated.
Caution if
allergic to
daisies
Supportive for
treatment;
equivocal for
prevention
Zinc
gluconate
4.5–23.7 mg Increases level of
zinc: amiloride
Decreases level
of zinc: ACE
inhibitors;
antibiotics;
cisplatin;
thiazides
Lowers HDL;
potential urinary
problems (BPH
and lithiasis).
Caution with
nasal spray gel:
loss of smell
Equivocal
Abbreviations: ACE, angiotensin-converting enzyme; CYP, cytochrome.
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tion and 1 report of anaphylactic shock and 2 reports of anaphylactic reaction in the
early 1990s from Sweden. Data are lacking about the safety of A paniculata for preg-
nant or breastfeeding women and should be avoided. In addition, some experimental
reports indicate that A paniculata might have a contraceptive effect; therefore, its use
should be avoided in men or women attempting to conceive.
Overall, the evidence suggests that A paniculata alone or in combination with E sen-
ticosus could be effective in the treatment of uncomplicated acute upper respiratory
tract infection.
Vitamin C (Ascorbic Acid)
Ascorbic acid is a water-soluble vitamin necessary to form collagen, cartilage, absorp-
tion of iron, and formation of blood vessels. It is found naturally in fruits (eg, citrus) and
vegetables.
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was heightened following the publication in 1970 of Nobel Prize winning scientist Linus
Pauling’s book Vitamin C and the common cold. He followed that by conducting
several meta-analyses demonstrating a decrease in the incidence and in the number
of days of illness following the use of vitamin C. Since then, controversy has arisen with
several trials reporting a benefit (mainly in populations who had low vitamin C intake or
< physical stress) and others reporting no benefit. Initial reviews indicated that despite
the heterogeneity of the studies, supplementation with vitamin C at doses of 1 g/d or
more consistently decreased the duration or alleviated the symptoms of the common
cold.11,12 In 2007, a meta-analysis by the Cochrane review group13 attempted to
answer the question: does vitamin C in doses of 0.2 g daily or more, reduce the inci-
dence, duration, or severity of the common cold when used either as continuous
prophylaxis or at the onset of cold symptoms.
Data from 11 different trials involving 3294 cold episodes where participants initi-
ated supplementation at the onset of cold symptoms were included. The data from
the therapeutic trials do not provide convincing evidence of reduced duration of colds
when treatment commenced after common cold symptoms began. Eight trial arms,
which included 2753 separate respiratory episodes for which cold severity was
assessed, were also reviewed. Analysis of these results similarly found no meaningful
difference between vitamin C and placebo groups in the severity of cold episodes
when treatment commenced after common cold symptoms began.
Questions remain about the overall efficacy of vitamin C in the treatment of common
cold symptoms. Although no firm conclusions can be drawn, some evidence suggests
the following strategies could be helpful: (1) vitamin C is more effective in reducing
cold symptoms and duration if the initiation of treatment is within 24 hours of the onset
of symptoms; (2) vitamin Cmay bemore effective in subjects with a low level of vitamin
C or who are undergoing high physical or mental stress; (c) higher doses of vitamin C
(4 g or higher) are more effective than lower doses. None of the vitamin C common
cold trials reported evidence that vitamin C is harmful in doses that were tested.
Echinacea (Echinacea angustifolia, Echinacea purpura, Echinacea pallida)
Echinacea species is widely used and marketed to improve the immune system
response during colds and flu. The exact mechanism of action for the immune-stim-
ulating effects of Echinacea preparations remains unclear. Four compounds are
believed to contribute to the immunomodulatory activity of Echinacea extracts: alka-
mides, glycoproteins, polysaccharides, and caffeic acid derivatives. These seem to
activate the alternate complement pathway components, and increased levels of T
lymphocytes and natural killer cells.14 In addition, Echinacea extracts increase the
macrophage proliferation and phagocytosis, as well as secretion of interferon, tumor
necrosis factor, and interleukin-1 (in vitro and in vivo).15–17 A Cochrane Review iden-
tified 9 trials (N 5 1126) with a total of 10 Echinacea groups diagnosed with common
cold symptoms, randomized and treated with Echinacea.18 Pressed juices (stabilized
with alcohol), alcohol tinctures, or tablets made from dried extracts were the forms of
Echinacea used. Outcome measurements were heterogeneous. Treatment groups
often used different instruments, timing of measurements, type of analysis, and
descriptive statistics. Among the 2 trials with no comparison groups, 1 study among
children receiving pressed juice of E purpurea herb reported positive results.19
When Echinacea preparations were compared with placebo as treatment, a significant
effect was reported in 9 comparisons, a trend in 1, and no difference in 6. Overall, the
clinical evidence for the efficacy of Echinacea for treating common cold symptoms
remains unclear.
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Goldenseal is native to eastern North America and is traditionally used by Native
Americans for the treatment of inflammation of the respiratory, digestive, and urinary
tracts. The 2 primary alkaloids found in goldenseal are berberine and hydrastatine.
Goldenseal has a strong astringent property, which is traditionally used to help ease
the discomfort of sore throat. Herbalists often recommend goldenseal in combination
with Echinacea for the treatment of colds and flu. However, there are currently no well-
designed studies evaluating goldenseal either alone or in combination with Echinacea.
Glodenseal is not recommended for pregnant or breastfeeding women.
Zinc
Zinc is an essential mineral that is naturally present in some foods (mollusks, oysters,
meat, poultry, beans, nuts, whole grains, cereals, and so forth), and available as a -
dietary supplement. Data from National Health and Nutrition Examination Survey
(NHANES III) indicate that 35% to 45% of adults aged 60 years or older had zinc
intakes less than the estimated average requirement of 6.8 mg/d for elderly women
and 9.4 mg/d for elderly men.20 Mild to moderate degrees of zinc deficiency can impair
the function and activity of the immune system, particular T lymphocytes.21,22 Zinc is
commonly used for a variety of conditions such as wound healing, skin ulcers, and
smell and taste disorders. It is also marketed in a variety of forms for treatment of viral
infections such as herpes simplex and URI.
Initial evidence from rigorous scientific trials of zinc and its effects on cold symp-
toms came from inoculation studies.23,24 Neither trial found a direct effect on viral
shedding, in either magnitude or duration. A more recent randomized, double-blind,
controlled trial of 100 employees of the Cleveland Clinic using zinc gluconate (13.3
mg) every 2 hours reported significant reduction in the duration of symptoms of the
common cold.25 A 7-month placebo-controlled trial26 (15 mg zinc sulfate daily as
a prophylactic, 15 mg twice daily after onset of cold and until symptoms resolved)
reported a drop in the mean number of colds (1.2 vs 1.7; P 5 .003), the mean number
of cold-related absences (0.9 days vs 1.3 days; P 5 .04), and shorter duration of cold
symptoms in the zinc group versus placebo (P<.0001).
A meta-analysis27 identified 8 trials using zinc gluconate on patients in whom colds
were developing de novo in the community. Doses of zinc gluconate used ranged from
4.5 to 23.7 mg. The odds ratio for the presence of any cold symptoms at 7 days was
0.52 (95% confidence interval, 0.25–1.2) indicating that the evidence for effectiveness
of zinc lozenges in reducing the duration of common colds is still lacking. Overall, the
current evidence is weak for the efficacy of zinc gluconate lozenges in reducing cold
duration.
Zinc is considered relatively safe when taken at recommended doses. Few studies
report side effects such as nausea, vomiting, or diarrhea. High-dose zinc has also
been associated with a potential reduction in (1) serum copper level, (2) lymphocyte
stimulation, and (3) high-density lipoprotein (HDL) and a higher incidence of urinary
problems among men, such as benign prostatic hyperplasia (BPH) and renal lithiasis.
Recent warnings regarding intranasal gel/spray have been posted by the US Food and
Drug Administration for possible loss of smell.
Other Therapies
Chinese herbs and formulas have also been evaluated for their potential benefit in
treating the common cold. A Cochrane meta-analysis28 identified 14 studies involving
2440 patients. All studies were rated of low or poor quality. There was high probability
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tested in nearly all trials. In 6 studies, 5 herbal preparations were found to be more
effective at enhancing recovery than the control; in the other 8 studies, 5 herbal prep-
arations were shown to be equal to the control. Based on this review, the investigators
concluded that they were unable to recommend any kind of Chinese herbal prepara-
tion for the common cold.
Recently, over-the-counter products (such as Airborne) marketed for the treatment
and prevention of the common cold have gained particular notoriety and popularity. A
review of this product reveals that contains several ingredients such as zinc (8 mg),
Echinacea (350 mg), and vitamins A, C, E, riboflavin, minerals (sodium, magnesium,
selenium, potassium) as well as other herbs such as ginger, Chinese vitex, forsythia,
and so forth. A review of the literature and the manufacturer’s Web site highlight
several testimonials but no scientific evidence of efficacy.RHINOSINUSITIS/ALLERGIC RHINITIS
The CDC defines rhinosinusitis (previously referred to as sinusitis) as an inflammation
of the mucosa of the sinuses and paranasal structures. It affects 31 million individuals
in the United States each year with an estimated annual cost of $5.8 billion.29 Patients
with bacterial sinusitis often report symptoms for more than 7 days, facial and/or teeth
tenderness and purulent nasal discharge. Viruses account for most cases of rhinosi-
nusitis and most cases resolve spontaneously. Rhinosinusitis remains the fifth leading
reason for which antibiotics are prescribed. Antibiotics should be reserved for patients
with bacterial symptoms. Surveys indicate that 24% to 32% of subjects with chronic
rhinosinusitis use herbal therapy either alone or in combination with other
treatments.30
Allergic rhinitis is a common condition. Current estimates indicate that more than 50
million people in the United States suffer from allergic rhinitis. It is the most prevalent
chronic condition in patients less than 18 years of age. People affected by the condi-
tion often report fatigue and upper respiratory symptoms. Allergic rhinitis also leads to
40% to 80% of cases of chronic rhinosinusitis.31
In this section, themost common natural supplements marketed for the treatment of
rhinosinusitis are reviewed.
Vitamin C (Ascorbic Acid) and Other Vitamins
Vitamin C is reported to inhibit histamine secretion by white blood cells.32 There seems
to be an inverse relationship between the ascorbic acid levels in the plasma and hista-
mine levels. Initial studies show that oral supplementation of vitamin C can reliably
lower blood histamine levels.33 In a prospective trial, blood levels of several vitamins
and minerals were evaluated in children (n5 24, mean age 9.2 years) with chronic rhi-
nosinusitis and compared with healthy controls (n5 20). Vitamin C, vitamin E, copper,
and zinc levels were significantly lower in the chronic sinusitis group compared with
controls.34 Vitamin C might hold promise in the management of rhinosinusitis;
however, evidence at this time does not allow for a definite conclusion.
Urtica dioica (Stinging Nettle)
Urtica dioica, also known as stinging nettle, has been traditionally used to treat allergic
rhinitis. The exact mechanism of action is not known; however, studies do indicate that
the plant is nutrient dense and that histamine, serotonin, and acetylcholine are present
in the plant’s hairs.35 The authors could not identify any clinical studies on the use of
stinging nettle for sinusitis; however, in 1 randomized, double-blind clinical trial,
Common Respiratory Diseases 303subjects (n5 69) who took freeze-dried (300 mg twice daily) Urtica dioica for the treat-
ment of allergic rhinitis achieved positive results. All treated subjects reported
improved global assessments, with 58% noting symptom abatement and 48%
recording equivalent or increased response withUrtica dioica compared with previous
medicine.36 The safety of stinging nettle for women who are pregnant or breastfeeding
has not been established. Caution is advised for patients with diabetes, bleeding
disorders, and those on diuretics.
Bromelain
Bromelain, a proteolytic enzyme obtained from pineapple, has commonly been used
to treat rhinosinusitis as an antiinflammatory and mucolytic.37 Bromelain seems to thin
nasal secretions38 in addition to its proteolytic activity at inflammatory sites, which is
believed to promote the inhibition of proinflammatory prostaglandin biosynthesis.39
A study of children with acute sinusitis reported faster symptom recovery in children
on bromelain compared with standard treatment.40 This confirmed findings from an
earlier double-blind study in which 85% of patients with acute and chronic sinusitis
receiving bromelain had complete resolution of inflammation of the nasal mucosa
(P<.05) compared with 40% in the placebo group.41 Initial studies on bromelain
seem to be encouraging but more evidence is needed.
Bromelain oral dosage is typically 500 to 1000 mg/d. Side effects include allergic
reaction to bromelain, indigestion, nausea, and diarrhea. The safety of bromelain for
pregnant or nursing women, children, or people with liver or kidney disease is not
known.
Quercetin
Quercetin is found in many foods such as onions and apples. Its antiinflammatory
activity seems to be a result of its antioxidant and inhibitory effects on inflamma-
tion-producing enzymes.42,43 Quercetin is also found to stabilize mast cells, which
inhibit release of histamine.44,45 Clinically, quercetin seems to be helpful in the
management of allergic rhinitis and seems to be therapeutically similar to cromolyn
sodium and oral antihistamine. In a small study (n5 12) a nasal spray formulation con-
taining an extract of quercetin was given immediately after the appearance of charac-
teristic allergic nasal symptoms. All patients experienced a rapid and significant
symptom relief of nasal symptoms, comparable with the effect of antihistamine and
chromoglicate preparations. The effect was felt within minutes after the administration
and lasted for several hours.46 Despite the positive initial evidence, no additional
studies have been published to confirm these findings.
The common oral dose of 400 to 500 mg 3 times per day is typically used. Quercetin
is generally safe. At large doses, there are some anecdotal reports of joint pain and
gastric discomfort.
Butterbur (Petasites hybridus)
Butterbur is a plant in the daisy family (Asteraceae). Butterbur is a robust plant with thick
rhizomes and large rhubarb-like leaves that contain active compounds believed to be
petasins, a group of sesquiterpenes. Butterbur was used traditionally as a remedy for
headache and inflammation. Clinical studies suggests that butterbur (standardized
extractZe339;1 tablet 3 timesdaily)mayeffectivelypreventallergic rhinitis similar to fex-
ofenadine (Allegra) andcetirizine (Zyrtec) in susceptible individuals.47,48Howeverastudy
focusing on intermittent rhinitis is conflicting and suggest that it is no better than
placebo.49 The evidence is encouraging that butterburr may prevent allergic rhinitis
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tion should avoid rawbutterbur extract becauseof thepotential for hepatotoxicity. Avoid
if pregnant, breastfeeding, or allergic to butterbur.Other Therapies
Acupuncture
The World Health Organization identifies acupuncture as an effective treatment of
allergic rhinitis, including hay fever. Several small trials report beneficial effect for
allergic rhinitis and allergies. For example a 2004 randomized clinical study compared
active versus sham acupuncture for 12 months in 40 consecutive patients with allergic
rhinitis and a positive skin test. For 1 allergen, mugwort, a greater reduction in levels of
specific immunoglobulin E (IgE) (P5 .019, 0.039) and skin test reaction (P5 .004) was
seen in the group receiving active acupuncture compared with the group receiving
sham acupuncture.50 However, a recent systematic review identified 7 randomized
controlled trials (RCTs), generally of poor quality, with the exception of 2 high-quality
studies, as assessed by Jadad scale.51 A wide variety of outcomes were measured
but most assessed symptom severity on a visual analog scale. A meta-analysis failed
to show any benefits of acupuncture treatment on symptom severity scores or serum
IgE measures that could not have been accounted for by chance alone. Acupuncture
studies looking at the treatment of sinusitis did not show an advantage over conven-
tional treatments.52,53 These findings were confirmed by a recent systematic review of
7 high-quality RCTs.54 Two RCTs compared acupuncture with oral pharmacologic
medications and reported positive results in favor of acupuncture. One study reported
favorable effects of acupuncture on a rhinitis symptom score and 1 found positive
results for a nasal symptom score compared with placebo acupuncture. Three
RCTs failed to demonstrate a beneficial effect of acupuncture in treating or preventing
symptoms of allergic rhinitis.
Overall the evidence for the effectiveness of acupuncture for the symptomatic treat-
ment or prevention of allergic rhinitis remains mixed. Studies fail to show beneficial
results for seasonal allergic rhinitis although some suggest evidence of effectiveness
in the management of perennial allergic rhinitis.ASTHMA
Asthma is a chronic inflammatory disease of the airways characterized by reversible
airflow restrictions and associated symptoms of wheezing, chest tightness, and short-
ness of breath.55,56 In the United States, it affects 22 million people of all ages, races,
and ethnic groups, and is 1 of the most common chronic diseases of childhood.56,57
There are clear allopathic guidelines for treatment according to disease severity,57 but
the use of CAM for asthma is widespread. A survey by the National Asthma Campaign
in the United Kingdom found that 60% of people with moderate asthma and 70%with
severe asthma had used CAM to treat their condition, and of the minority who had not
yet used CAM, 67% indicated they would consider using CAM for their asthma in the
future.55 A survey of CAM use in by people with asthma or rhinosinusitis in the United
States found that 42% of the study population had used some form of CAM for their
condition in the 12 months before the study.58
The most popular forms of CAM for asthma include herbs, breathing techniques
(including mind-body relaxation techniques), homeopathy, and acupuncture.55,59
Studies on why patients turn to CAM treatments reveal a desire for personal control
over treatment, the perception of effectiveness, safety, being more natural or holistic,
Common Respiratory Diseases 305as well as dissatisfaction with side effects, costs, provider interaction, and
approaches of conventional methods (Tables 2 and 3).60–64
Given the prevalence of CAM use for asthma, and because most patients (>80%)
who use CAM are simultaneously using allopathic treatments,58,65 it is important for
allopathic physicians to be aware of the common types CAM treatments being
used, and be able to counsel patients on current evidence for efficacy, risks, and
potential interactions between therapies, especially involving herbs and
pharmaceuticals.
Herbals
Herbal therapy is 1 of the most popular forms of CAM treatments for asthma.55,58,59
Four of the 5 classes of drugs currently used to treat asthma (b2 agonists, anticholiner-
gics, methylxanthines, and cromones) have origins in herbal treatments going back at
least 5000 years.66 For example, ephedrinewas developed from the traditional Chinese
herbal remedy ma huang, tea leaves are the herbal origin of theophylline, and caffeine,
found in tea and coffee, is a member of the same family as theophylline, and has been
used for centuries as a treatment of asthma.65,67 Like many CAM treatments, scientific
evidence evaluating the effectiveness of herbal therapy for asthma has beenmarred by
poor study quality and flawed study design. Three systematic reviews of herbal thera-
pies for asthma were conducted in the last decade, and although they used slightly
different methodologies, they all came to similar conclusions. In the most recent and
most comprehensive review,65 the investigators found 27 studies assessing 21 herbal
preparations involving 1925 participants that met the entry criteria of the review. Small
sample sizes, disparate outcome measurements, and relatively short-term follow-up
prevented any overall clear conclusion as to efficacy and long-term safety of herbal
therapy for asthma. Mean duration of therapy was only 8 weeks. There were large vari-
ations in the typesof pulmonary functionmeasurements, symptomscores, and typesof
subjective assessments, greatly limiting the ability of the review to perform combined
outcome data assessments or subgroup analysis. With these limitations in mind, the
results of a few herbs merit comment.
Boswellia serrata
Boswellia is a branching tree found in India, North Africa, and the Middle East, and
a close relative of the Biblical incense frankincense. The gummy oleoresin found under
the bark has been used for years in Ayurvedic medicine in India and in African coun-
tries for the treatment of a variety of diseases, including arthritis and asthma. Its mech-
anism of action in asthma is believed to be a result of its antiinflammatory properties,
because resin extracts inhibit leukotriene synthesis and release.68 One 6-week
randomized controlled trial of 80 adults with asthma reported improvements in forced
expiratory volume in 1 second (FEV1), forced vital capacity (FVC), number of asthma
exacerbations, and wheezing69 but subsequent reviewers expressed concerns with
significant differences in baseline characteristics between groups, raising questions
about appropriate randomization, and about whether the groups were comparable.
The Cochrane Review identified another small, double-blind RCT of 40 patients that
reported improvements in FEV1 as a percentage of predicted, but translated into
only modest changes in actual FEV1, and had no improvements in peak expiratory
flow rate (PEFR) or FVC%.
Boswellia seems to be generally safe, although extensive studies of safety and toler-
ability are lacking and there have been some references to gastrointestinal side effects
in humans (epigastric pain, heartburn, nausea, and diarrhea) and findings of hepato-
toxicity in 1 study of mice. Caution is advised in patients taking agents metabolized
Table 2
Summary of natural supplements used for asthma treatments and their effectiveness
Name Suggested Dose Drug Interactions Side Effects
Scientific Evidence
of Efficacy
Boswellia serrata 300 mg 3 times daily
powdered gum resin
capsules
Inhibitor of cytochrome
P450 enzymes. May
impair absorption of
lipid-soluble medications
Generally well tolerated,
some reports of
gastrointestinal
symptoms
Limited evidence,
clinical effects
likely modest
Tylophora indica 250 mg once to 3 times
daily, 0.1% of
tylophorine per dose
No specific interactions
noted
Severe nausea/vomiting,
required antiemetic in 1
trial to mask it from
placebo (lessened if
capsule form rather than
whole leaf
Limited evidence of
short-term
effectiveness for
FEV1 and attack
frequency
Propolis Not known May have antiplatelet
effects. In vitro studies
show additive effects to
antimicrobials. Some
tinctures have ethanol
Potent allergen and
sensitizing agent,
caution in hypersensitive
individuals
Limited evidence of
effectiveness in 1
small study
Purple passion fruit
peel extract
150 mg/d of extract Insufficient information None known, limited data Equivocal
Selenium Studies:100 mg/d, (RDA
is 50 mg/d for adults)
Not recommended during
chemotherapy or
radiation therapy
because of potential
interference.
Combination with
b-carotene, vitamins C
or E seems to decrease
the effectiveness of
simvastatin and niacin
Seems well tolerated at
noted doses. Chronic
high selenium levels may
decrease sperm motility,
although effects on
fertility are not known
Not effective by
limited evidence
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Vitamin C Studies used 500 mg to
2 g/d. (RDA is 75 mg/d)
Diarrhea, renal lithiasis
in high doses
Not effective by fair
evidence
Vitamin E 500 mg/d. RDA is 15 mg/d Caution in combination
with anticoagulant and
antiplatelet medications.
May increase
cyclosporine levels
Seems well tolerated up
to 1000 mg/d for
short periods Not
recommended for
long-term dosing
Not effective by
limited evidence
Magnesium 300–400 mg/d May interact and decrease
effectiveness of several
antibiotics and thyroid
hormone
Seems tolerated up
to 1200 mg/d
Equivocal
Fish oil/omega-3 fatty
acids
Variable, 2–3 g/d Theoretic increase in risk of
bleeding in combination
with ASA or warfarin
Seems well tolerated.
Caution re: heavy metal
contaminants
Not effective by good
evidence
Abbreviations: ASA, acetylsalicylic acid; FEV1, forced expiratory volume in 1 second; RDA, recommended daily allowance.
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Table 3
Summary of alternative therapies used for treatment of asthma and their effectiveness
Name Details Side Effects
Scientific Evidence
of Efficacy
Acupuncture Variable points
chosen depending
on study
Rare; generally
well tolerated
Not effective but
poor quality
studies
Homeopathy Variable agents used Not reported Not effective by
good evidence
Osteopathic
manipulation
Various techniques
used
Not reported Equivocal
Mind-body relaxation Various: relaxation,
hypnosis, yoga
Not reported,
generally
recognized
as safe
Limited evidence
benefit in
quality of life
measurements
Kilgore & Najm308by the liver’s cytochrome P450 enzymes, as boswellia may moderately or potently
inhibit these enzymes, and in patients taking lipid-soluble medications, because the
gum resin of boswellia has been reported to lower cholesterol and triglyceride levels,
and may bind to/impair absorption of these medications. Boswellia powdered gum
resin capsules 300 mg 3 times daily were used in the original trial.70Tylophora indica
Tylophora is a climbing perennial plant that grows in India. Its mechanism of action
seems to a result of the effects of tylophorine, a major alkaloid of Tylophora, on adrenal
hormone stimulation, depressing cell-mediated immunity and suppression of IgE
mediator release. In the Cochrane Systematic Review, Tylophora showed impressive
short-term improvements in clinical outcomes of attack frequency and symptom
severity, and moderate improvements in lung function measurements but positive
effects were not evident after 12 weeks, and investigators noted that this herb may
not be suitable for chronic use because it is also associated with severe gastrointes-
tinal side effects, sufficient to lead 1 of the investigators to include an antiemetic agent
in the placebo comparator to mask treatment group assignment. In an earlier system-
atic review63 identifying 5 randomized clinical trials, 3 demonstrated moderate
improvement of symptoms, 1 with improved FEV1, and 2 studies showed no signifi-
cant improvement compared with placebo for the 2-week trials. Different formulations
and dosing regimens have been reported from various studies, but doses of 250 mg 1
to 3 times daily, 0.1% of tylophorine per dose, have been standardized. Safety data
only exist for 6- to 14-day exposures, and adverse effects mainly seem to be gastro-
intestinal, including nausea and vomiting, and these seem to be reduced if the leaves
are taken in capsule form instead of chewing.
Propolis
Propolis is a natural flavonoid-rich resin produced from the buds of conifer and poplar
trees then incorporated by bees into beeswax in combination with other bee secre-
tions. There is preliminary in vitro and in vivo evidence that propolis suppresses the
lipoxygenase pathway of arachidonic acid metabolism and decreases the synthesis
of prostaglandins and leukotrienes involved in inflammation. Propolis has also demon-
strated antiiflammatory properties through its free radical-scavenging properties, as
well as antimicrobial effects from several flavonoids.
Common Respiratory Diseases 309A small clinical trial71 reported some improvement in lung parameters (FEV1, PEFR,
and forced expiratory flow 25%–75%), as well as a reduction in nocturnal attacks
compared with placebo.
Numerous case reports have demonstrated that propolis may be a potent allergen
and sensitizing agent, and therefore it should be used cautiously in hypersensitive indi-
viduals. There are no standard dosing recommendations, and preparations have been
found to have highly variable compositions.
Purple Passion Fruit Peel Extract
A recent short-term Iranian study72 of 42 patients involving a double-blind, random-
ized, placebo-controlled trial of 150 mg/d of purple passion fruit peel (PFP) extract,
a novel mixture of bioflavonoids, on asthma symptoms showed some promising
results. The prevalence of wheeze, cough, and shortness of breath was reduced
and FVC improved significantly in the group treated with PFP extract (P<.05)
compared with placebo; however, the absolute improvement was relatively small,
with unclear clinical significance and no significant improvement was observed in
FEV1. The investigators point to several possible intriguing mechanisms supporting
a beneficial effect of PFP on asthma, citing effects of flavonoids in reducing asthmatic
inflammation through their known antioxidant, antiallergic, and antiinflammatory prop-
erties, as well as an observed effect on lowering nitrous oxide production. There was
no adverse effect reported by any of the study participants, making this a compelling
compound for further study in larger and longer trials.
Other Herbal Preparations
Several other herbs demonstrated improvements in subjective asthma symptoms
(eucalyptol, ginger, pulmoflex, Tj-96, Liu-Wei-Di-Huang-Wan, Shen-Ling-Bia-Shu-
San, and Jai-Wei-Si-Jun-Zi-Tang) or short-term steroid reduction in severe asthmatics
(eucalyptol), but the validity of the study results were significantly undermined by poor
study design and reporting quality. Studies of herbal therapies as a part of traditional
Chinesemedicine (TCM) also had frequent limitations; none of the trials used a placebo
control, there were variable or unspecified ingredients, and after direct query by the
Cochrane reviewers, it turned out that more than 95% of the study investigators did
not understand the concept of randomization, preventing any meaningful conclusion
as to their efficacy.
Summary Herbal Treatments for Asthma
Boswellia, Tylophora and purple passion fruit peel extract show some promise in
asthma treatment, but further studies of efficacy and side effects that are larger and
better designed are needed before these can be recommended for general use.
Supplements
Interest in treating asthma through dietary supplements is often based on concepts
related to potential antiinflammatory and antioxidant effects as well as the idea that
modern western diets are deficient in elements necessary or beneficial to normal
lung function. Elements that have been reputed to play potential roles include sele-
nium, vitamins C and E, and omega-3 fatty acids in fish oil.Selenium
Selenium gained interest in treating asthma based on studies that observed asthma
patients with lowered selenium status and lowered activity of the selenium-dependent
Kilgore & Najm310enzyme glutathione peroxidase in asthma patients along with observational reports
that selenium supplementation might be beneficial to patients with intrinsic asthma
because of its important role in the cellular elimination of hydroperoxides. A Cochrane
Systematic Review of the effects of selenium in asthma from 200473 was only able to
locate a single, small, double-blind RCT of 24 patients who were receiving standard
asthma therapy. Those receiving a daily supplement of 100 mg sodium selenite for
14 weeks showed significant increases in serum selenium level and platelet gluta-
thione peroxidase activity, and improvement in subjective asthma symptoms but
failed to demonstrate improvements in objective spirometry measurements. The
investigators speculated that although it is possible that the supplemental dose given
was too low and that a dose of 200 to 250 mg might be more beneficial based on other
observational studies, they concluded that there is insufficient evidence to assess the
use of selenium in clinical practice.
A subsequent double-blind RCT in 200774 using 100 mg for 24 weeks in 97 patients,
documented significant increases in selenium serum levels, but showed nonsignificant
improvements in quality of life and no significant changes in lung function testing,
leading the investigators to conclude that selenium supplementation offered no clin-
ical benefit in chronic asthma.
Vitamin C
As 1 of the key antioxidant vitamins that is abundant in the extracellular fluid, vitamin C
has been a supplement of interest in asthma, especially because adults and children
with asthma have been found to have lower concentrations of vitamin C compared
with normal subjects, and prior observational studies have showing that low vitamin
C intake is associated with pulmonary dysfunction. It has been speculated that
patients with asthma may have low supplies of vitamin C or an increased demand
for vitamin C in the face of an oxidant load resulting in depletion. A 2009 Cochrane
Review75 of vitamin C use in seasonal, exercise-induced, and chronic asthma located
a 9 studies meeting review criteria, with varying study protocols ranging from single
dosing between 500 and 2000 mg, to daily supplementation between 500 and 1500
mg for time ranges of 1 week to 6 months. Because of poor data reporting and variable
methodology, the investigators were only able to combine data for FEV1 measure-
ments in 4 of the studies, and commented that the method of randomization, alloca-
tion concealment, and blinding was not always clear, leaving the results open to bias.
They found essentially no change in any of the study parameters, including lung func-
tion, need for steroids, and subjective symptom scores, and concluded that further
study with better trial design and larger-scale studies are needed.
Vitamin E
In a small double-blind RCT of another well know antioxidant, vitamin E, in daily doses
of 500 mg for 6 weeks failed to show any demonstrable benefit in lung function,
symptom scores, bronchodilator use, or serum IgE levels in atopic adults with mild
to moderate asthma.76
Magnesium
Magnesium has been recognized as useful intravenously for treating acute asthma
exacerbations,77 but data on its oral use for treating chronic asthma in outpatient
settings have mostly shown no benefit. A small double-blind RCT study of 17 patients
given 400 mg of magnesium a day for 3 weeks after previous exposure to a low
magnesium diet showed improvement in asthma symptom scores, but no change in
airflow parameters, airflow reactivity to methacholine, or bronchodilator use.78
Common Respiratory Diseases 311Another well-done double-blind RCT study of 100 asthmatic patients who received
supplementation with magnesium (450 mg/d) for 16 weeks showed no beneficial
effect in any outcome measurement of asthma control, including airflow or reactivity
measurements, symptom scores, or bronchodilator use.79 A recent double-blind
RCT study of 37 children and adolescents using 300 mg of magnesium a day for 2
months demonstrated fewer asthma exacerbations, less salbutamol use, and
decreased responsiveness to methacholine challenges and skin test responses to
antigens, but had no change in spirometry values.80Fish Oil and Omega-3 Fatty Acids
Given the known influence of inflammatory mediators on asthma, fish oil supplemen-
tation has naturally been a topic of significant interest for treatment and prevention of
asthma, because of the known antiinflammatory effects of omega-3 fatty acids
present in fish oil. Epidemiology studies have shown that populations (such as Eskimo
communities) with diets high in fish have low rates of asthma, and as diets in other
communities have become higher in saturated fats, asthma incidence has
increased.81 Two very small double-blind RCTs of only 10 and 16 patients with exer-
cise-induced asthma using fish oil capsules containing 3.2 g of eicosapentaenoic acid
and 2.0 g of docohexaenoic acid daily for 3 weeks demonstrated clinical improvement
in pulmonary function response to exercise, decreased bronchodilator use, and
decreased sputum inflammatory mediators.82,83 However, a Cochrane Systematic
Review in 200281 failed to demonstrate any clinical benefit of the use of n-3 marine
fatty acids supplementation for asthma. In the comprehensive review, the investiga-
tors identified 9 studies that met study inclusion criteria, and found no convincing
evidence that supplementation of diet with marine n-3 fatty acids leads to an improve-
ment in asthma symptoms, asthma medication usage, bronchial hyper-reactivity or
FEV1, nor was there evidence of risk or adverse effects identified. They concluded
with 2 interesting caveats: first, that the studies concentrated mainly on supplementa-
tion of marine n-3 fatty acids rather than eating more fish per se, and that perhaps
there are other elements in the original food source that could have beneficial effects
for asthma; second, that much of the interest in n-3 fatty acid supplementation for
asthma began in the era when the neutrophil was considered to possibly have an
important role in the pathogenesis of asthma, because the most profound antiinflam-
matory effects of n-3 fatty acids are on neutrophil function and mediator generation.
However, eosinophils and mast cells are now believed to be more important effector
cells in asthma, and therefore this may explain their relative lack of efficacy, given that
n-3 fatty acids lack significant antiinflammatory effect on eosinophils and mast cells in
vitro.
In an extremely detailed and comprehensive review of omega-3 fatty acids in
asthma by the Agency for Healthcare Research and Quality in 2004,84 the investiga-
tors were unable to derive any definite conclusion about benefit because of the paucity
of evidence from well-designed, well-conducted, and adequately powered studies,
citing limitations caused by missing data, flawed designs, and noncomparable study
parameters, but again found no significant evidence of harm. They made reference to
an ongoing prospective study at that time looking at the use of omega-3 fatty acids for
asthma prevention in children (Childhood Asthma Prevention Study), which was at its
conclusion in 2007, that also failed to identify any beneficial protective effect.85
Another more recent British systematic review in 2006 came to the same conclusions,
and recommended a large, randomized, controlled study to effectively answer the
question about omega-3 effects on asthma.86
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Other than some mild improvement in asthma symptom scores for magnesium
supplementation that was not confirmed in a well-designed double-blind RCT, none
of the supplements demonstrated any benefit for use in chronic asthma.
Other Complementary Therapies
Acupuncture
Acupuncture is a form of therapy derived from TCM involving the stimulation of points
on thebodywith the use of needles for therapeutic or preventative purposes. Thepoints
are derived from TCM theory and relate to the meridians, a system that purportedly
allows the flow of Qi through the body, blockages of which are believed to cause health
problems.87 Three comprehensive systematic reviews in 2002, 2003, and 2006 evalu-
ated the effect of acupuncture in asthma, each approaching the literature with slightly
different criteria and review techniques. Martin and colleagues88 searched for all RCTs
since 1970 that compared acupuncture at real and placebo points and used at least 1
objective measurement of pulmonary function. They took estimates from the 11 trials
that met inclusion criteria, and combined estimated standardized mean differences
between acupuncture and placebo to estimate the overall effect. The Cochrane
Systematic Review87 was only able to pool data for 2 outcomes (PEFR and global
assessment of well-being) in the 12 RCTs involving 350 patients that met their criteria.
The systematic review by Passalacqua and colleagues64 looked at a variety of CAM
modalities in asthma, including acupuncture, without doing meta-analysis.
Despite the differences in approach, all 3 reviews arrived at similar conclusions. (1)
With minor exceptions, the reviews basically found no significant evidence of efficacy
for acupuncture in asthma, whether in lung function parameters, subjective symptom
measurements, or with medication usage. (2) As with herbal medications, study
quality, sample size, missing information, and heterogeneity in measurements limited
data pooling and the ability to draw useful, statistically significant conclusions. (3)
Reviewers commented in particular about the challenge unique to acupuncture
research in choosing appropriate placebo acupuncture points, noting that studies
varied in choosing nonmeridian points versus nonindicated but legitimate acupunc-
ture points for placebo control. The points used in the sham arm of some studies
were used for the treatment of asthma in others (according to TCM). Further hetero-
geneity occurs with needle depth, duration of insertion, choice of laser versus needle,
and the choice of either standardized points versus allowing treating providers to indi-
vidualize and customize points depending on diagnoses made using a TCM nosology
quite foreign to western physicians and research methods. They concluded with clear
recommendations for larger studies with particular attention to the nature of sham/
control points and including a no-treatment control arm in addition to sham groups,
as well as the need for studies to include patients with more severe asthma.Homeopathy
Homeopathy, founded by Hahnemann at the beginning of the 1800s, relies on the prin-
ciple that symptoms of a disease can be cured by the same substances that provoke
them when they are ultra diluted. Homeopathic remedies are selected according to
symptoms and prepared with a special technique involving repeated dilutions. A
recent systematic review64 identified 3 studies in asthmatic patients conducted with
good methodology that showed no or marginal effects. Another well-done, random-
ized, double-blind, placebo-controlled trial over 12 months in pediatric patients89
also failed to demonstrate any benefit in terms of peak flow rates, use of medication,
Common Respiratory Diseases 313symptom scores, days off school, asthma events, or global assessment of change for
homeopathic remedies as prescribed by experienced homeopathic practitioners.
The 2004 Cochrane review90 identified 6 trials with a total of 556 people. The inves-
tigators noted significant methodological flaws with many studies, precluding pooling
of results, but were not able to find evidence of benefit.
Manual therapy
Evidence for various forms of manual therapy (chiropractic, osteopathic manipulation,
various physical therapy techniques) in asthma is mixed. Recent Cochrane
Reviews91,92 found no significant benefit for chiropractic manipulation or the Alex-
ander physical therapy technique, and noted methodological flaws in many studies
limiting informed conclusions. A randomized, single-blind, controlled trial of osteo-
pathic manipulation therapy in 140 pediatric asthma patients showed a statistically
significant improvement in PEFRs from 7 L per minute to 9 L per minute. However,
the validity of the conclusions are potentially hampered by the nonblinded evaluator,
and the different osteopathic manipulative therapy (OMT) techniques of different
providers. Further study addressing these shortfalls was recommended.
Mind-body (relaxation) therapies
Three comprehensive review studies93 came to mixed conclusions about the role for
mind-body, relaxation, or breathing technique in asthma, with methodological flaws in
study design once again posing challenges to deriving valid conclusions. Progressive
muscle relaxation, breathing retraining, and yoga appeared to have potential benefits
for lung function, self-perceived well-being, and quality of life measurements, with
further better designed studies recommended to derive more valid conclusions. A
recent British RCT94 demonstrated improvements in quality of life measurements
but there seemed to be no effect on asthma pathophysiology and therefore no change
in the need for antiinflammatory medication. Small studies on the use of mental
imagery, hypnosis, and biofeedback showed some promising results for these
approaches that although clearly safe, also need further research to validate their
effectiveness.95–97
Summary of Other Complementary Therapies in Asthma
Mind-body techniques seem to have some benefit for quality of life indicators in
asthma; homeopathy seems to have no evidence of benefit and poor quality studies
hamper conclusions about acupuncture and manual therapies.
COPD
COPD is a preventable and treatable disease that is frequently associated with
smoking, and characterized by chronic airflow limitation that is not fully reversible, is
usually progressive, and is associated with abnormal inflammatory response to
noxious particles or gases.98 Common symptoms are chronic and progressive dysp-
nea and sputum production. In the United States, COPD affects more than 5% of the
adult population and is the fourth leading cause of death and the twelfth leading cause
of morbidity.99 Although there is no cure for COPD, smoking cessation is the only ther-
apeutic intervention shown to reduce disease progression. Unsatisfactory treatment
outcomes and side effects from conventional drugs, such as steroids and theophyl-
line, contribute to the increasing popularity of CAM and, in particular, herbal medi-
cine.100 Studies show that between 33% and 41% of COPD patients admit to using
some form of CAM101,102; the most common types include herbal and nutritional
supplements, as well as garlic, acupuncture, and homeopathy. As with asthma, the
main source of information on CAM practices are most often relatives, friends, and
Kilgore & Najm314advertisements, with only a small number of the patients consulting with their physi-
cians about CAM. This makes it important for physicians to be knowledgeable about
the scientific evidence for efficacy and safety of these practices (Table 4).
Herbals
There is a long history of using herbal remedies to treat COPD, particularly in China,
India, and other Asian countries. Herbal expectorants, based on extracts from Hedera
helix (ivy) or Thymus vulgaris (thyme) also enjoy considerable popularity in many Euro-
pean countries.100 However, evenmore so than with asthma, quality evidenced-based
studies on the use of herbal treatments in COPD are lacking. In the first and only
comprehensive systematic review of the topic, done in 2006,100 the investigators
reviewed English, Chinese, and German literature, finally identifying 14 eligible
RCTs, with placebo-controlled comparisons in 6. As with the asthma literature, the
methodological quality was generally low, with problems caused by small sample
size, lack of double blinding, use of a placebo control, unclear herbal content, and
nonstandardized evaluation tools.
Panax ginseng
The roots of slow-growing perennial Panax plants have been used in China for
more than 2000 years for various ailments. The major active components of
ginseng are a diverse group of steroidal saponins, labeled ginsenosides, which
may have a variety of actions, including potential antiinflammatory effects that
may play a role in asthma. A well-designed double-blind RCT of 92 moderately
severe (FEV1 50%–65%) COPD patients in Israel demonstrated that 100 mg of
ginseng extract capsules twice daily for 3 months resulted in significant improve-
ment in all parameters of pulmonary function testing, including maximum voluntary
ventilation, maximum inspiratory volume and VO2 max with no observed side
effects.103 The improvement in airflow in major and peripheral airways as well
as improvement in exercise capacity parallels previous studies on athletes. This
was interpreted by the investigators as indications of positive effects on respira-
tory muscle strength possibly caused by postulated neurotransmitter-like actions.
Another very small Chinese study of 20 patients using a daily intravenous formu-
lation of 3 herbs with Panax ginseng as the main ingredient for 14 days also
showed improvements in pulmonary function (FEV1 and vital capacity) as well as
6-minute walk time and Borg symptom scores.104
In general, animal studies indicate that ginseng has very few toxic effects for either
acute or chronic (up to 2 years) use, but some in vitro studies show that Panax ginseng
may inhibit the aggregation of platelets, reduce platelet adhesiveness, reduce interna-
tionalized normalized ratio (INR), and reduce warfarin concentrations and increase its
clearance.
DCBT1234-Lung KR
A randomized, double-blind, placebo-controlled clinical study was done in India on
105 patients comparing 6 months of a plant-based formulation of 3 herbs (Bryonia
alba, Drosera peltata [or sundew], and Cephaelis ipecacuanha [better known as
ipecac]) against the combination of oral salmeterol, theophylline, and bromhexine
and both against placebo.105 Patients treated with DCBT 1234-Lung KR showed
statistically significant (95% level) improvement in FEV1 and PaO2 compared with sal-
butamol1theophylline1bromhexine, and equivalent control of symptoms such as
dyspnea, wheezing, cough, expectoration, disability, and sleep disturbances, both
Table 4
Summary of alternative treatments for COPD
Name
Suggested Dose or
Treatment Details Drug Interactions Side Effects
Scientific Evidence
of Efficacy
Panax ginseng 200–400 mg/d or 100–200
mg of a standardized
ginseng extract (4%
ginsenosides)
May inhibit the
aggregation of
platelets, reduce
platelet adhesiveness
reduce INR and
warfarin concentration
Generally well tolerated Equivocal
DCBT1234-lung KR Unknown 2 components (Bryonia alba
and ipecac) have potentially
serious adverse effects, both
rated as unsafe
Equivocal
Nutritional
supplementation
Variable Not noted Not effective by good
evidence
Acupuncture Variable points chosen
depending on study
N/A Rare; generally well tolerated Possibly effective for
dyspnea symptoms
Osteopathic manipulation Various techniques used N/A One study report worsened air
trapping and expiratory flow
Not effective by
limited evidence;
may cause harm
Abbreviations: INR, internationalized normalized ratio; N/A, not applicable.
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Kilgore & Najm316better than placebo. No mention was made in the article about adverse effects in any
of the study arms. Concerns expressed by subsequent letter responses challenged
the use of nonstandard allopathic medications as control, pointing out that the combi-
nation of oral salmeterol and theophylline poses known cardiovascular risks to COPD
patients, and expressed concern about the issue of heavy metal poisoning associated
with plant-based Ayurvedic medicines.
Drosera species have been used for hundreds of years for respiratory tract prob-
lems, and it is a fairly commonly used medicine as a solitary ingredient or as part of
combination medications in roughly 200 to 300 registeredmedications. Testing of indi-
vidual Drosera constituents reveals antiinflammatory, antispasmodic, and antibacte-
rial effects, with minimal adverse effects although safety data are limited. Although
purported to have some evidence of antitumor and antiinflammatory effects, Bryonia
has been rated as unsafe with serious gastrointestinal, renal, and neurologic adverse
effects reported. Ipecac is well known in the United States from its previously recom-
mended role as an emetic in cases of suspected pediatric poisoning. That recommen-
dation was rescinded several years ago, and there have been reports of myopathies
and death with chronic use.68,70 Although this is a promising and interesting study
done with reasonable methodology, further study is clearly needed regarding the effi-
cacy, safety, and adverse effects of the individual herbal ingredients.
Other Herbals
Improvement in at least 1 measure of pulmonary function have been shown with Salvia
miltiorrhiza, Echinacea and Hedera helix leaf extract, but the studies were small, failed
to use placebo controls, or had other methodological flaws. A small Japanese RCT106
using 2.5 mg of the traditional Japanese herbal medicine Hochuekkito (a mixture of 10
raw Japanese herbs, mixed in set proportions) given orally 3 times a day for 6 months
showed improvements in several markers of systemic inflammation and serum preal-
bumin levels in older patients with COPD, but did not address pulmonary function.
Most small studies of various TCM herbal preparations for COPD have significant
methodological flaws that limit useful interpretation or recommendations.
Nutritional Supplementation
Although up to one-third of patients with COPD have some degree of malnutrition,
often becoming severe in advanced or end-stage disease, it has been unclear whether
malnutrition plays a causative role in clinical deterioration or whether it is merely
a marker of other processes intrinsic to the disease.107,108 In a 2005 Cochrane
Systematic Review of the topic,109 the investigators identified 14 studies involving
487 patients meeting review criteria, the majority pertaining to outpatient-based oral
supplementation for at least 2 weeks to undernourished patients with COPD. Using
meta-analysis, they found no evidence that simple nutritional supplementation confers
benefit to patients with COPD in terms of clinical outcomes including measuring
effects on anthropometric, functional exercise, pulmonary mechanics, peripheral
muscle function, and health-related quality of life derived from validated scales.
Triceps skinfold thickness was marginally higher with supplementation than control,
but was not associated with any other meaningful health improvements, suggesting
that some fat was deposited in the patients receiving nutritional supplementation
but this change does not constitute a worthwhile response to therapy. However, it
is worth noting that 2 weeks may be a short period of supplementation.
The investigators note that explanations for a poor response to nutritional support
have included increased metabolism, diet-induced thermogenesis, tissue hypoxia,
the influence of increased levels of soluble tumor necrosis factor-alpha receptors,
Common Respiratory Diseases 317and medications such as corticosteroids, and that further research into combinations
of nutrition with anabolic substances may prove worthwhile. However, 3 recent well-
done, adequately powered, double-blind, randomized, placebo-controlled trials of an
anabolic steroid (nandrolone decanoate)110 and creatine combined with exercise
training111,112 showed no difference in pulmonary function or functional exercise
capacity. A prospective, double-blind, randomized, placebo-controlled trial of meges-
terol acetate of 128 patients did show a 4-mm decrease in PaCO2, as a result of its
known stimulatory effect on ventilation, and increased appetite associated with
a 3.2-kg weight gain; but the weight was mainly fat and again, there was no benefit
on respiratory muscle function or functional exercise tolerance.113
Other single placebo-controlled studies showed similar negative results for pome-
granate juice, N-acetylcysteine, and vitamin E.
Manual Medicine
Theosteopathicmedical profession hasdevelopeda variety of techniques purported to
improve pulmonary function by targeting various aspects of the musculoskeletal,
neuronal, and lymphatic components of the pulmonary system.114,115 Previous litera-
ture consisting of small, nonrandomized studies has failed to provide a clear picture
as to the efficacy and role of OMT in the treatment of COPD. Researchers at the Kirks-
ville College of OsteopathicMedicine performed awell-designed, double-blind, RCT of
a single session of multitechnique OMT versus sham therapy in 35 patients more than
65 years of age, looking for evidence of immediate measurable changes in pulmonary
function. They did find statistically significant evidence of pulmonary function change,
but in the wrong direction: OMT-treated patients had worsening of residual volume,
indicatingmore air trapping, and a decrease in forced expiratory flow. The investigators
concluded that further study looking at the effect of individual techniques and studying
longer-term pulmonary function responses to OMT will be important to understand if
COPD should be a contraindication to the use of this therapy.
Acupuncture
Several small single-blind RCTs of between 4 and 10 weeks of acupressure and
acupuncture have been done in patients with COPD, some with, some without
placebo/sham controls.116–118 Taking into account significant variations in technique,
choice of outcome measurements, and methodological flaws in randomization and
blinding of evaluators, all studies showed improvement in subjective symptoms of
dyspnea, with 2 studies showing improvements in either FEV1 or 6-minute walk
distance. No report of adverse effects was made, and acupuncture was generally
well tolerated. Acupuncture shows promise at least in improving subjective symptoms
of dyspnea in COPD, but better designed, larger trials are clearly needed before solid
recommendations can be made.
Summary of CAM Therapies for COPD
Acupuncture may play a role in improving walking distance and subjective symptoms of
dyspnea,althoughbetter studiesareneeded.Otherwise there is littleevidence tosupport
herbal therapy, and fairly good evidence that nutritional supplements are ineffective and
osteopathicmanipulation ispotentially harmful untilmoreextensive research is available.SUMMARY
The self-medication phenomenon in upper respiratory tract infections, rhinosinusitis,
asthma, and COPD are significant and will continue to increase. Current level of
Kilgore & Najm318evidence is poor because of the small number of good quality studies, small sample
size, short duration, and variation in the composition of the herbal interventions or
therapies. The current review points to several potential therapies that could be effec-
tive either alone, or as adjunct to conventional therapies.
Caveats and Cautions
One of the positive motivations for using CAM is perceived safety. However, there
are risks with the use of herbal remedies including drug interactions, inconsistent
dosing, contamination, and natural toxicity.119 These risks are compounded by the
tendency of patients to report neither their use of herbal treatments nor suspected
adverse reactions of the herbal therapies to their physicians, compared with
conventional over-the-counter medications, and because herbal therapy users
tend to self-medicate or take the advice of a friend or relative, they are unlikely
to consult any practitioner at all on the use of herbal products.120,121 Blanc and
colleagues122 raise the concern that patients’ use of alternative treatments may
delay appropriate use of conventional medicines and thus, increase the risk for
life-threatening complications.REFERENCES
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